NCT04764942 - Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

June 17, 2026

Study Completion Date

December 17, 2027

Conditions

Recurrent Multiple MyelomaRefractory Multiple Myeloma

Interventions

DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given PO

DRUG

Pomalidomide

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Selinexor

Given PO

PROCEDURE

X-Ray Imaging

Undergo x-ray imaging

PROCEDURE

Computed Tomography

Undergo PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester